financetom
Business
financetom
/
Business
/
Why Calidi Biotherapeutics (CLDI) Stock Is Getting Hammered
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Calidi Biotherapeutics (CLDI) Stock Is Getting Hammered
May 31, 2024 10:58 AM

Calidi Biotherapeutics Inc ( CLDI ) shares are trading lower by 30.7% to $0.21 during Friday’s session after the company announced a definitive agreement for the immediate exercise of certain Series B and C warrants to buy up to 10.698 million shares of its common stock at 20 cents per share.

This exercise, expected to generate approximately $2.1 million before fees and expenses, involves warrants issued in April 2024 with terms of twelve and four months, respectively. In return for the immediate exercise, Calidi will issue new unregistered warrants to purchase up to 10.698 million shares at 30 cents per share, exercisable upon shareholder approval, with a term of five and a half years.

Additionally, new Series B-1 and C-1 warrants, also totaling 10.698 million shares at 20 cents per share, expiring in five years, will be issued. The offering is expected to close around June 3, pending customary conditions. The proceeds will fund Calidi’s clinical and pre-clinical programs, operating expenses and working capital.

See Also: Are Rate Cuts Imminent After Fed’s Preferred Inflation Data Holds Steady?

Should I Sell My CLDI Stock?

When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.

Shares of Calidi Biotherapeutics ( CLDI ) have decreased by 97.99% in the past year. An investor who bought shares of Calidi Biotherapeutics ( CLDI ) at the beginning of the year would take a loss of $1.23 per share if they sold it today. The stock has risen 4.48% over the past month, meaning an investor who bought shares on Apr. 1 would see a capital loss of $0.29.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Calidi Biotherapeutics ( CLDI ) stock currently has an RSI of 80.75, indicating overbought conditions.

For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.

CLDI has a 52-week high of $5.00 and a 52-week low of $0.14.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Italy's Enel ups minimum dividend, to invest over $45 bln by 2027
Italy's Enel ups minimum dividend, to invest over $45 bln by 2027
Nov 17, 2024
MILAN, Nov 18 (Reuters) - Italy's biggest utility Enel said on Monday it would lift its minimum dividend for the 2025-2027 period to 0.46 euros per share from 0.43 euros previously. In its updated three-year plan, the state-controlled group said it would invest around 43 billion euros ($45 billion), 7 billion euros more than previously envisaged in the 2024-2026 strategy....
China's Huawei starts taking pre-orders for Mate 70 smartphone
China's Huawei starts taking pre-orders for Mate 70 smartphone
Nov 17, 2024
BEIJING (Reuters) - China's Huawei on Monday announced that it had started taking pre-orders for its Mate 70 smartphone model, in a statement on its official WeChat account. ...
Hong Kong's WH Group seeks shareholder approval for US unit spin-off, listing
Hong Kong's WH Group seeks shareholder approval for US unit spin-off, listing
Nov 17, 2024
Nov 18 (Reuters) - Hong Kong-based WH Group ( WHGRF ), the world's largest pork producer, is seeking shareholder approval for the proposed spin-off of its U.S. unit Smithfield Foods and plans to list the business in the U.S. WH Group ( WHGRF ) said on Sunday the underlying pre-money valuation of the Smithfield Foods, the world's largest pork processor,...
Global offshore wind industry poised to miss big targets as obstacles mount
Global offshore wind industry poised to miss big targets as obstacles mount
Nov 18, 2024
(Reuters) - After a year of canceled projects, broken turbines, and abandoned lease sales, the global offshore wind industry no longer has much chance to hit the lofty targets set by governments in the U.S., Europe and elsewhere, marking a setback for efforts to fight climate change. The technology forms a big part of government strategies to advance renewable energy...
Copyright 2023-2026 - www.financetom.com All Rights Reserved